A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

Question

Six frontier AI models put this at 5% by 22 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

5% — the median of 6 frontier models, resolving by 2036-10-22.

Answer

Gemini (Google): 3% — Genomic and microenvironmental heterogeneity across solid tumor types makes a single universal curative regimen biologically implausible by 2035. No candidate in active Phase 1/2 trials demonstrates pan-solid-tumor complete durable remission, requiring a de novo discovery to clear Phase 3 in under 8 years. Tumor-agnostic approvals like pembrolizumab for MSI-H cancers produce cures in only a small fraction, far short of a broad-spectrum cure. Proof of universal targetable neoantigens or breakthroughs in solid-tumor cell therapies showing >80% durable response across tissue types would raise odds.

Answer

Claude (Anthropic): 2% — No approved therapy cures broad-spectrum metastatic solid tumors; biology and trial timelines make this near-impossible by 2035. Metastatic solid tumors are biologically heterogeneous; no single mechanism has shown durable complete remission across tumor types even in trials. Drug development from current early-stage platforms (cell therapy, bispecifics, oncolytic virus) to broad approval typically takes 10-15+ years, leaving little runway. Regulatory agencies like FDA/EMA have never approved a 'curative' label for metastatic solid cancer broadly, only disease-specific incremental survival gains.

Answer

GPT (OpenAI): 6% — It turns on whether one regimen can show durable complete remissions across diverse metastatic tumor biology in pivotal trials. FDA/EMA would need compelling randomized, tumor-agnostic durability data and an acceptable safety profile before 22 October 2036. Past tissue-agnostic approvals target molecular subsets, not broad metastatic cancers; durable cures across common solid tumors have not occurred. Odds rise sharply if a platform produces multi-year complete-remission results in phase II across pancreatic, lung, colorectal, and breast cancers by 2030.

Answer

Grok (xAI): 12% — No late-stage asset yet shows pan-solid-tumor complete durable remissions that regulators would label curative. FDA/EMA would need a Phase 3 readout of high CR rates across ≥3 metastatic histologies by ~2032 to allow 2034 approval. Base rate of first-in-class oncology approvals that rewrite survival curves is ~1 per decade; none in 8 years has been pan-solid curative. A surprise pan-cancer neoantigen or in-vivo CAR trial with 40%+ 2-year CRs would shift this, but none is even in Phase 2 today.

Answer

DeepSeek (DeepSeek): 8% — This turns on whether a pan-tumor curative regimen clears Phase III and FDA review within roughly eight years. No pan-solid-tumor curative exists today; even the best modern agents (checkpoint inhibitors, CAR-T in solid tumors) yield single-digit complete response rates in… FDA approval requires Phase III overall-survival benefit, typically 5-8 years from trial start; a regimen entering trials now would barely reach review by 2035. Tissue-agnostic approvals (pembrolizumab 2017, larotrectinib 2018) cover rare biomarkers, not broad metastatic solid tumors, so the precedent is narrow.

Answer

Qwen (Alibaba): 2% — No therapy in oncology history has achieved broad-spectrum durable remission across metastatic solid tumors, and the trial timeline alone nearly rules it out. Even if a candidate entered Phase I today, FDA approval for a novel mechanism typically requires 8-12 years of trials; nothing in current pipelines shows broad-spectrum… Checkpoint inhibitors cure a minority of melanoma and MSI-high tumors but fail across most solid tumor types; no pipeline agent demonstrates pan-tumor complete remission… A surprise would require a fundamentally new mechanism (e.g., universal neoantigen targeting) already in late-stage trials with extraordinary efficacy data—no such…

A broad-spectrum curative therapy for metastatic solid tumors is approved before 2035.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.

An mRNA-based therapeutic cancer vaccine receives full FDA approval for curative intent before 2032.

A definitive cure for at least three of the top five deadliest cancers is approved before 2040.

A universal cure or definitive therapeutic regimen eliminating all major human cancers is approved by a major regulatory agency before 2050.